Hormone replacement therapy: The perspectives for the 21st century

Maturitas

Volumn 32, Issue 1, 1999, Pages 11-17

  Genazzani, A R ^a   Gambacciani, M ^a  

^a Via Roma 55 56100 ^*  (Italy)

Author keywords

Hormone replacement therapy; Postmenopausal women; Selective estrogen receptor modulators

Indexed keywords

ESTROGEN; GESTAGEN; RALOXIFENE;

ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; COGNITION; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE;

ADULT; AGED; CLIMACTERIC; FEMALE; FORECASTING; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0033013842     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00109-1     Document Type: Article

References (73)

1. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 117:1992;1038-1041.
2. Grady D., Rubin S.M., Petitti D.B. et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
3. Session D.R., Kelly A.C., Jewelewicz R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril. 2:1993;277-284.
4. Grodstein F., Stampfer M.J., Colditz G.A. et al. Postmenopausal hormone therapy and mortality. New Engl J Med. 336:1997;1769-1775.
5. Elia G., Bergman A. et al. Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence. Obstet Gynecol Surv. 49:1993;509-517.
6. Paganini-Hill A. Does estrogen therapy protect against Alzheimer's disease? Osteoporosis Int 1997;7 (Suppl 1):S12-S17.
7. Paganini-Hill A., PhD V.W., Henderson M.D. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 156:1996;2213-2217.
8. Sherwing B.B. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psyconeuroendocrinology. 13:1988;345-357.
9. Sherwing B.B. Estrogenic effects on memory in women. Ann New York Acad Sci. 734:1994;213-230.
10. Penotti M., Nencioni T., Gabrielli L. et al. Blood flow variation in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. Am J Obstet Gynecol. 169:1993;1226-1232.
11. Chesnut III C.H. Osteoporosis: a world-wide problem? Christiansen C., Overgaard K. Osteoporosis 1990. 1990;36-41 Osteopress ApS, Copenhagen.
12. Melton III L.J. Epidemiology of age related fractures. Aviola L.V. The Osteoporotic Syndrome: Detection, Prevention and Treatment. 3rd:1990;36-41 Wiley-Liss, New York, NY.
13. Heaney R.P. Pathophysiology of osteoporosis. Am J Med Sci. 312(6):1996;251-256.
14. Noteloviz M. Osteoporosis: screening, prevention, and management. Fertil Steril. 59:1993;707-725.
15. Riggs B.L., Wahner H.W., Dunn W.L., Mazess R.B., Offord K.P., MeltonIII L.J. Differential changes in bone mineral density of the appendicular and axial skeleton with aging. J Clin Invest. 67:1981;328-335.
16. Gambacciani M., Spinetti A., De Simone L. et al. The relative contribution of menopause and aging to postmenopausal vertebral osteopenia. J Clin Endocr Metab. 77:1993;1148-1152.
17. Nilas L., Christiansen C. The pathophysiology of peri-and postmenopausal bone loss. Br J Obstet Gynaecol. 96:1989;580-587.
18. Wallach S., Henneman P. Prolonged estrogen therapy in postmenopausal women. J Am Med Assoc. 171:1959;1637.
19. Lindsay R. Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol. 156:1987;1347.
20. Gambacciani M., Spinetti A., Taponeco F. et al. Longitudinal evaluation of premenopausal vertebral bone loss: effects of a low dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol. 8:1994;392-394.
21. Kanis J.A. Estrogens, the menopause, and osteoporosis. Bone. 19(Suppl 5):1996;185S-190S.
22. Schneider D.L., Barrett-Connor E.L., Morton D.J. Timing of postmenopausal estrogen for optimal bone mineral density: the Rancho Bernardo Study. J Am Med Assoc. 277:1997;543-547.
23. Eriksen E.F., Kassem M., Langdahl B. European and North American Experience with HRT for the prevention of osteoporosis. Bone. 19(Suppl 5):1996;179S-183S.
24. Christiansen C., Riis B.J. 17β-Estradiol and continuos norethisterone:a unique treatment of established osteoporosis in elderly women. J Clin Endocrinol Metab. 71:1990;836-841.
25. Bush T.L. The epidemiology of cardiovascular disease in postmenopausal women. Ann New York Acad Sci. 592:1990;263-271.
26. Grady D., Rubin S.M., Petitti D.B. et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
27. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:1991;47-56.
28. Ottesen B., Pedersen A.T. Physiological effects of ovarian hormones: clinical aspects and compliance. Eur Heart J. 17:1996;20-26.
29. Lobo R.A., Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril. 61:1994;592-595.
30. Bush T.L., Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev. 7:1985;80-104.
31. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc. 273:1995;199-208.
32. Sarrel P.M. Ovarian hormones and the circulation. Maturitas. 12:1990;287-298.
33. Cagnacci A., Soldani R., Carriero P.L. et al. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab. 74:1992;1396-1400.
34. Rosenberg L., Armstrong B., Phil D., Jick H. Myocardial infarction and estrogen therapy in postmenopausal women. New Engl J Med. 294:1976;1256-1259.
35. Ross R.K., Paganini-Hill A., Mack T.M. et al. Menopausal oestrogen therapy and protection from death from ischemic heart disease. Lancet. 18:1981;858-862.
36. Barrett-Connor E., Laasko M. Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Atherosclerosis. 10:1990;531-534.
37. Nabulsi A.A., Folsom A.R., White A. et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. New Engl J Med. 328:1993;1069-1075.
38. Stampfer M.J., Colditz G.A., Willet W.C. et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. New Engl J Med. 325:1991;756-762.
39. Birkhauser M.H. Hormone replacement therapy and estrogen-dependent cancers. Int J Fertil Menopausal Stud. 39(Suppl 2):1994;99-114.
40. Birkhauser MH. Hormone replacement therapy and breast cancer risk revisited in 1997. Menopause Review 1997;2:35-47.
41. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 85:1995;304-313.
42. Kenemans P., Scheele F., Burger C.W. Hormone replacement therapy and breast cancer morbidity, mortality and recurrence. Eur J Obstet Gynecol Reprod Biol. 71(2):1997;199-203.
43. Whitehead M.I., Townsend P.T., Pryse-Davies J. et al. Effects of various type and dosages of progestogens on the postmenopausal endometrium. J Reprod Med. 27:1982;539.
44. Campbell S., Minardi J., McQueen J. et al. Endometrial factors: the modifying effect of progestogen on the response of the postmenopausal endometrium to exogenous estrogens. Postgrad Med J. 54:1978;59.
45. Gambrell R.D., Massey F.M., Castanedo T.A., Ugenas A.Y., Ricci C.A., Wright Y.M. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol. 55:1980;732-738.
46. Parker S.L., Tong T., Bolden S. et al. Cancer statistics, 1996. CA Cancer J Clin. 65:1996;5-27.
47. von Schoultz B. HRT and breast cancer risk, what to advise? Eur J Obstet Gynecol Reprod Biol. 71(2):1997;205-208.
48. Kuller L.H., Cauley J.A., Lucas L., Cummings S., Browner W.S. Sex steroid hormones, bone mineral density, and risk of breast cancer. Environ Health Perspect. 105(Suppl 3):1997;593-599.
49. Roy J.A., Sawka C.A., Pritchard K.I. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? J Clin Oncol. 14(3):1996;997-1006.
50. Ewertz M. Hormone therapy in the menopause and breast cancer risk: a review. Maturitas. 23:1996;241-246.
51. Stanford J.L., Weiss N.S., Voigt L.F., Daling J.R., Habel L.A., Rossing M.A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc. 274(2):1995;137-142.
52. Sutherland R.L., Hall R.E., Pang G.Y.N. et al. Effects of medroxiprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res. 48:1988;5084-5091.
53. CO human breast cancer cells by progestins. Implication for endocrine therapy. Cancer Res. 45:1985;167-173.
54. Wren B.G., Eden J.A. Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause. 3:1996;4-12.
55. Spicer D., Pike M.C., Henderson B.E. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology. 4:1990;49.
56. Eden J.A., Bush T., Nand S., Wren B.G. A case-control study of combined continuos estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause. 2:1995;67-72.
57. Stoll B.A. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol. 25:1989;1909-1913.
58. DiSaia P.J., Grosen E.A., Odicino F. et al. Replacement therapy for breast cancer survivors. A pilot study. Cancer. 76:1995;2075-2078.
59. Wile A.G., Opfell R.W., Margileth D.A. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg. 165:1993;372-375.
60. Marchant D.J. Estrogen-replacement therapy after breast cancer: risks versus benefits. Cancer. 71:1993;2169-2176.
61. Lobo R.A. Hormone replacement therapy. Estrogen replacement after treatment for breast cancer? Lancet. 341:1993;1313-1314.
62. Whitehead M., Lobo R.A. Consensus Conference: progestogen use in postmenopausal women. Lancet. 2:1988;1243-1244.
63. Jorndan V.C., Phelps E., Lingren J.U. Effect of anti-estrogens on bone in castrated and in intact female rats. Breast Cancer Res Treat. 10:1987;31-35.
64. Black L.J., Sato M., Rowley E.R. et al. Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:1994;63-69.
65. Evans G.L., Bryant H.U., Magee D. et al. The effects of Raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology. 134:1994;2283-2288.
66. Sato M., Kim J., Short L.L. et al. Longitudinal and cross-sectional analysis of Raloxifene effects on tibiae from ovariectomized rats. J Pharmacol Exp Ther. 272:1995;1251-1259.
67. Baker V.L., Draper M., Paul S. et al. Reproductive endocrine end endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab. 83(1):1998;6-13.
68. Boss S.M., Huster W.J., Neild J.A. et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 177(6):1997;1458-1464.
69. Gottardis M.M., Jordan V.C. The anti-tumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47:1987;4020-4024.
70. Delmas P.D., Bjarnason N.H., Mitlak B.H. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl J Med. 337(23):1997;1641-1647.
71. Walsh BW, Lewis HK, Wild RA, et al. Effects of raloxifene on serum lipids coagulation factors in postmenopausal women. JAMA 1998;279:1445-1451.
72. Notelenbos C. A promising new women's health drug. Eur Menopause J. 4:1997;135-136.
73. Lauritzen C. HRT prescribing guidelines: dream or reality? Int J Gynaecol Obstet. 52(Suppl 1):1996;S3-S9.